Virna Schuck

Supplementary Figure 13 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 13. Swim lane plot of responses to FHD-286 monotherapy in all patients with AML or MDS (asterisks) who had received ≥1 dose of FHD-286. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; QD, once daily; SD, stable disease; TF, treatment failure.

Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.

Supplementary Figure 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 1. Flow of patients through Study FHD-286-C-002 (monotherapy dose escalation).

Supplementary Figure 15 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 15. Gene expression signatures of stemness and differentiation in the blast compartment of individual patients on UMAP projection.

Supplementary Data 1 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Data_ FHD-286-C-002 study protocol

us (code pays fourni par la source)

Supplementary Figure 12 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 12: Case 2. Peripheral blast count (top) and absolute neutrophil count (bottom) in a 25-year-old male patient with R/R treatment-related AML with KMT2A rearrangement treated with FHD286 7.5 mg QD.

Supplementary Figure 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 6. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 18; R/R AML; FHD-286 7.5 mg QD dose group.

Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.

Supplementary Figure 11 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 11. Case 1. Analysis of bone marrow cell morphology with Wright-Giemsa staining in a 47-year-old male patient with complex karyotype treated with FHD-286 10 mg once daily.

Supplementary Figure 2 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 2. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 33; R/R AML; FHD-286 2.5 mg QD dose group.

Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.

Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Courtney Denton Dinardo, Amir Tahmasb Fathi, Ashwin Kishtagari, Kapil N. Bhalla et autres

Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.